Cigna Group Croissance future
Future contrôle des critères 1/6
Cigna Group devrait augmenter ses bénéfices et son chiffre d'affaires de 6.8% et de 4.2% par an respectivement. Le BPA devrait croître de de 10.6% par an. Le rendement des capitaux propres devrait être 19.1% dans 3 ans.
Informations clés
6.8%
Taux de croissance des bénéfices
10.64%
Taux de croissance du BPA
| Healthcare croissance des bénéfices | 18.3% |
| Taux de croissance des recettes | 4.2% |
| Rendement futur des capitaux propres | 19.13% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 20 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Seeking Alpha • May 18
Cigna: Shares Marching To Full Recovery
Summary Cigna Group is reiterated as a "Buy," driven by strong Q1 2026 results, raised guidance, and sustained business momentum. CI’s pharmacy and behavioral health segments are fueling revenue growth, while divestitures and PBM reform temporarily temper 2026 earnings. Shares trade at a 25% discount to a $377 fair value estimate, offering potential 15% annual total returns through 2031. Cigna’s robust balance sheet, market-leading dividend coverage, and growth catalysts in biosimilars and behavioral health underpin the investment thesis. Read the full article on Seeking AlphaArticle d’analyse • May 04
The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...
Mise à jour du récit • May 02
CI: Leadership Transition And Buybacks Will Support Future Share Upside
Analysts have increased their price target on Cigna Group by about $1. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their models.Mise à jour du récit • Apr 17
CI: Leadership Transition And Buybacks Will Drive Future Upside
Analysts have trimmed their average price target on Cigna Group by about $0.38 to roughly $338.42, reflecting small updates to fair value estimates, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Cigna Group plans a leadership transition, with current CEO David M.Mise à jour du récit • Apr 02
CI: Leadership Transition And Onsite Care Expansion Will Drive Future Upside
Analysts have slightly refined their view on Cigna Group, trimming the price target by a fraction to $338.79 as updated assumptions for revenue growth, profit margins, and future P/E bring the model into closer alignment with their latest expectations. What's in the News Cigna Group plans a leadership transition, with David M.Mise à jour du récit • Mar 19
CI: Onsite Care Expansion And Leadership Transition Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group from about $336.67 to roughly $338.80. This reflects updated views on revenue growth, profit margins, and an anticipated forward P/E of around 13.43x.Mise à jour du récit • Mar 05
CI: Onsite Care Expansion Will Support Future Upside Potential
Analysts now set Cigna Group's fair value estimate at about $336.67, up from roughly $332.62, reflecting updated assumptions that incorporate slightly higher revenue growth, profit margins, and a lower future P/E multiple. What's in the News Cigna Group plans a leadership transition, with CEO David M.Mise à jour du récit • Feb 19
CI: Higher Margin Outlook And Onsite Care Expansion Will Support Upside
Analysts have modestly lifted their price target on Cigna Group to $332.62 from $326.92, citing updated assumptions that combine slightly lower revenue growth with a higher profit margin and a future P/E of 15.62. What's in the News A class action lawsuit has been filed against Express Scripts, Cigna, and Evernorth, alleging a rebate diversion scheme that used an offshore entity, Ascent, to collect billions of dollars in kickbacks labeled as fees instead of passing rebates through to pharmacy benefit management clients, including the Plumbers' Welfare Fund.Mise à jour du récit • Feb 04
CI: Onsite Clinic And Stable Assumptions Will Support Future Upside
Analysts have kept their price target for The Cigna Group broadly unchanged at about US$327, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions rather than any major shift in their outlook. What's in the News Hankook Tire America Corp.Mise à jour du récit • Jan 21
CI: Completed Buybacks And New Employee Clinic Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group slightly higher to US$326.92 from US$325.57, citing minor refinements to discount rate assumptions, revenue growth expectations, profit margin inputs, and the forward P/E multiple used in their models. What's in the News Hankook Tire America Corp.Mise à jour du récit • Jan 07
CI: Massive Share Buyback And Clinic Expansion Will Support Future Earnings Upside
Analysts have slightly reduced their price target for Cigna Group, trimming fair value by about $0.69 to $325.57 as they factor in a more moderate revenue growth outlook, along with a small improvement in expected profit margins and future P/E assumptions. What's in the News Hankook Tire America Corp.Mise à jour du récit • Dec 15
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Narrative Update on Cigna Group Analysts have slightly lowered their price target on Cigna Group by approximately $2 to around $326 per share, reflecting modest tweaks to assumptions on long term growth, profitability, and valuation multiples, while maintaining a broadly constructive outlook. What's in the News Cigna Group reported that between July 1 and September 30, 2025, it repurchased no additional shares under its existing authorization, having already completed the buyback of about 133.5 million shares, or 41.09% of shares outstanding, for roughly $34.44 billion since the program was announced in December 2018 (company filing).Mise à jour du récit • Nov 30
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Analysts have raised their price target for Cigna Group to $328.35 per share, citing moderate adjustments to key financial metrics. These include a higher projected future price-to-earnings ratio and continued expectations for growth and profitability.Mise à jour du récit • Nov 16
CI: Significant Buybacks And 2026 Guidance Will Drive Upside Momentum
Narrative Update on Cigna Group Analysts have lowered their price target for Cigna Group from $349.04 to $328.35. This change reflects adjustments for a slightly higher discount rate as well as revised expectations for revenue growth and profit margins.Mise à jour du récit • Nov 01
CI: Share Repurchase Momentum Will Drive Long-Term Shareholder Value Creation
Analysts have lowered their price target for Cigna Group from $369.13 to $349.04. This change reflects updated expectations around modestly higher revenue growth, which are offset by a slight dip in profit margin projections.Article d’analyse • Jul 10
The Cigna Group (NYSE:CI) Screens Well But There Might Be A Catch
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Article d’analyse • Jun 19
These 4 Measures Indicate That Cigna Group (NYSE:CI) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Mar 31
The Cigna Group: Compelling Exposure To Diversified Healthcare At A Discount Price
Summary Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth by reducing Medicare exposure and improving Commercial business. Despite industry challenges, Cigna achieved 8%-9% YoY EPS growth in 2023-2024, demonstrating strong cost discipline and effective management. The sale of Cigna's Medicare unit and focus on lower-cost biosimilars and streamlined care accessibility are key strategic moves for future growth. With an attractive valuation and minimal downside risk, Cigna stock is rated a BUY, offering at least 33% upside potential even in bearish conditions. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
Cigna Is A Buy: Market Overreaction Creates A Big Opportunity
Summary Cigna looks undervalued at under 10x earnings, with strong growth potential. Evernorth continues to expand, adding to the company’s long-term value. Large stock buybacks are supporting earnings per share and investor returns. Regulatory risks, rising costs, and competition remain challenges to watch. If Cigna meets its targets, the stock could rise 20-30% from here. Read the full article on Seeking AlphaSeeking Alpha • Jan 18
Cigna: Buy The Drop On This Undervalued Growth Stock
Summary Cigna's current valuation presents a compelling opportunity, trading at a forward PE of 9.9, significantly below its historical average of 12.0x. The company carries diversified revenue streams and consistent earnings growth, with Healthcare and Evernorth divisions driving strong performance and a 13% EPS CAGR over 10 years. Management targets 10-14% long-term annual EPS growth, supported by increased biosimilar adoption, behavioral health services growth, and aggressive share buybacks. CI's growing dividend and robust fundamentals make it an attractive choice for value and growth investors, despite potential regulatory and macroeconomic risks. Read the full article on Seeking AlphaSeeking Alpha • Dec 13
Cigna And The Risk Of PBMs - I'm Staying Out Above $230/Share
Summary Cigna faces significant risks due to potential healthcare reforms and scrutiny on PBMs, making it a "Hold" until it drops below $230/share. The US healthcare system's high costs and structural issues contribute to the uncertainty surrounding Cigna's long-term profitability and business model. Despite strong historical performance, the potential breakup of PBMs and legislative changes could drastically impact Cigna's future earnings and growth. The current valuation does not justify investment; Cigna's appeal lies in its fundamental strengths but is overshadowed by systemic risks and political uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Sep 26
Cigna: This Dividend Grower Could Be Worth Buying Now
Summary The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value. Cigna could be set up to generate strong total returns in the next couple of years. Read the full article on Seeking AlphaSeeking Alpha • Sep 19
Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'
Summary I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth. Despite low operating margins and elevated cost trends, Cigna's share repurchase program and SG&A optimization are expected to support future margin expansion and free cash flow growth. Read the full article on Seeking AlphaSeeking Alpha • Jul 29
Cigna Group: Services Focus Leads To Outperformance
Summary Cigna Group's medical memberships are focused on "services-only" commercial memberships. The fee-based rather than risk-based nature of these memberships makes Cigna more resilient to rising medical costs. The Evernorth segment should see high-single-digit growth for the foreseeable future, driven by Healthcare Services and specialty pharmacy Accredo. The low valuation coupled with the mid-single-digit earnings growth outlook makes Cigna stock attractive at current prices. Read the full article on Seeking AlphaSeeking Alpha • Jul 12
Cigna: Game Over For PBMs?
Summary Pharmacy Benefit Managers are increasingly in the spotlight of regulators and the media, potentially leading to government intervention. Express Scripts, Cigna's PBM, is responsible for nearly 75% of the company's revenue, which raises the question of whether CI stock is still a safe investment. This article discusses the potential implications in a scenario-based approach, focusing on segment profit, consolidated profit, dividend safety, and valuation. In addition, I share my thoughts on the recent opioid litigation in Arkansas and explain why I continue to sleep well with my investment in Cigna. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 312,622 | 7,911 | 10,117 | 11,225 | 10 |
| 12/31/2027 | 296,960 | 7,728 | 10,108 | 10,393 | 14 |
| 12/31/2026 | 284,004 | 6,622 | 9,039 | 9,393 | 14 |
| 3/31/2026 | 277,892 | 6,288 | 7,660 | 8,812 | N/A |
| 12/31/2025 | 274,900 | 5,957 | 8,389 | 9,601 | N/A |
| 9/30/2025 | 268,077 | 6,147 | 7,437 | 8,664 | N/A |
| 6/30/2025 | 262,023 | 5,018 | 3,944 | 5,292 | N/A |
| 3/31/2025 | 255,368 | 5,034 | 6,010 | 7,443 | N/A |
| 12/31/2024 | 247,121 | 3,434 | 8,957 | 10,363 | N/A |
| 9/30/2024 | 232,586 | 3,039 | 5,184 | 6,618 | N/A |
| 6/30/2024 | 217,940 | 3,708 | 7,960 | 9,398 | N/A |
| 3/31/2024 | 206,003 | 3,620 | 10,160 | 11,625 | N/A |
| 12/31/2023 | 195,265 | 5,164 | 10,240 | 11,813 | N/A |
| 9/30/2023 | 189,904 | 5,328 | 10,892 | 12,445 | N/A |
| 6/30/2023 | 186,137 | 6,677 | 11,414 | 12,902 | N/A |
| 3/31/2023 | 183,029 | 6,774 | 10,239 | 11,654 | N/A |
| 12/31/2022 | 180,518 | 6,704 | 7,361 | 8,656 | N/A |
| 9/30/2022 | 180,453 | 6,627 | 9,578 | 10,832 | N/A |
| 6/30/2022 | 179,460 | 5,491 | 8,402 | 9,668 | N/A |
| 3/31/2022 | 177,113 | 5,401 | 6,928 | 8,128 | N/A |
| 12/31/2021 | 174,069 | 5,370 | 6,037 | 7,191 | N/A |
| 9/30/2021 | 170,102 | 8,384 | 6,041 | 7,210 | N/A |
| 6/30/2021 | 166,769 | 8,151 | 4,915 | 5,986 | N/A |
| 3/31/2021 | 162,903 | 8,438 | 8,487 | 9,556 | N/A |
| 12/31/2020 | 160,401 | 8,458 | 9,256 | 10,350 | N/A |
| 9/30/2020 | 156,934 | 5,300 | 7,764 | 8,849 | N/A |
| 6/30/2020 | 154,535 | 5,263 | 9,339 | 10,415 | N/A |
| 3/31/2020 | 154,089 | 4,917 | 7,057 | 8,180 | N/A |
| 12/31/2019 | 153,566 | 5,104 | N/A | 9,485 | N/A |
| 9/30/2019 | 129,621 | 4,271 | N/A | 6,818 | N/A |
| 6/30/2019 | 102,522 | 3,692 | N/A | 4,981 | N/A |
| 3/31/2019 | 75,183 | 3,090 | N/A | 4,937 | N/A |
| 12/31/2018 | 48,650 | 2,637 | N/A | 3,770 | N/A |
| 9/30/2018 | 44,768 | 2,759 | N/A | 4,219 | N/A |
| 6/30/2018 | 43,800 | 2,547 | N/A | 4,830 | N/A |
| 3/31/2018 | 42,745 | 2,554 | N/A | 4,532 | N/A |
| 12/31/2017 | 41,806 | 2,237 | N/A | 4,086 | N/A |
| 9/30/2017 | 41,332 | 2,353 | N/A | 4,358 | N/A |
| 6/30/2017 | 40,723 | 2,249 | N/A | 5,035 | N/A |
| 3/31/2017 | 40,258 | 1,946 | N/A | 4,684 | N/A |
| 12/31/2016 | 39,838 | 1,867 | N/A | 4,026 | N/A |
| 9/30/2016 | 39,252 | 1,911 | N/A | 4,315 | N/A |
| 6/30/2016 | 38,761 | 2,002 | N/A | 3,017 | N/A |
| 3/31/2016 | 38,293 | 2,080 | N/A | 3,117 | N/A |
| 12/31/2015 | 37,876 | 2,094 | N/A | 2,933 | N/A |
| 9/30/2015 | 37,276 | 2,135 | N/A | 2,319 | N/A |
| 6/30/2015 | 36,644 | 2,122 | N/A | 2,175 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CI ( 6.8% par an) est supérieure au taux d'épargne ( 3.5% ).
Bénéfices vs marché: Les bénéfices de CI ( 6.8% par an) devraient croître plus lentement que le marché US ( 16.7% par an).
Croissance élevée des bénéfices: Les bénéfices de CI devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de CI ( 4.2% par an) devrait croître plus lentement que le marché de US ( 11.7% par an).
Croissance élevée des revenus: Le chiffre d'affaires de CI ( 4.2% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de CI devrait être faible dans 3 ans ( 19.1 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 09:05 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
The Cigna Group est couverte par 40 analystes. 17 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | Argus Research Company |
| Hua Ha | Baird |
| Andrew Mok | Barclays |